Charles River Laboratories
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.7% | -0.5% | -2.5% | +0.7% | -5.9% | +0.7% | -0.3% | -0.6% | -5.0% | +8.3% | -2.6% | |
| – | +11.4% | +3.7% | -10.1% | -0.3% | -6.1% | +7.4% | -2.4% | +4.2% | -5.6% | +2.9% | +2.7% | |
| – | +76.1% | +18.2% | -45.2% | +17.3% | -7.4% | +17.9% | -20.3% | +13.6% | +2.9% | -10.3% | +0.1% | |
| – | +76.1% | +18.2% | -45.2% | +17.3% | -7.4% | +17.9% | -20.3% | +13.6% | +2.9% | -10.3% | +0.1% | |
| – | -2.4% | +0.8% | -3.1% | -1.1% | -4.4% | +5.0% | +1.4% | -4.3% | -3.5% | -1.2% | +1.6% | |
| – | +29.8% | -5.0% | -3.4% | -3.7% | -17.1% | +4.2% | -3.7% | +8.2% | -1.1% | +20.3% | -3.7% | |
| – | – | – | – | – | -0.4% | -1.3% | +0.1% | -1.3% | +2.6% | – | – | |
| – | +7.3% | -0.8% | +0.3% | +1.5% | -8.9% | +0.9% | +2.2% | -0.5% | -5.4% | +10.0% | +1.2% | |
| – | -2.5% | -4.2% | -3.3% | -2.7% | -7.1% | -9.4% | -8.1% | -5.2% | -40.5% | -26.8% | +1.7% | |
| – | +6.6% | -1.9% | -6.2% | +0.0% | -3.7% | +8.0% | -4.1% | -2.4% | -3.4% | +20.8% | -1.2% | |
| – | +6.2% | -9.5% | -0.8% | +6.8% | -1.8% | +5.7% | +2.8% | +3.8% | -0.1% | -2.4% | +3.8% | |
| – | +4.5% | -99.4% | +22.3% | +1,234.4% | -100.0% | – | – | – | +2,216.3% | – | – | |
| – | +23.9% | -23.2% | +2.6% | +2.2% | +3.2% | +6.4% | -2.4% | +16.3% | -12.3% | -10.0% | +5.2% | |
| – | +5.3% | +0.5% | -9.4% | -3.4% | -3.7% | +12.1% | -7.1% | -6.3% | -3.4% | +26.1% | -1.6% | |
| – | +8.8% | +1.2% | +2.3% | +1.6% | -8.5% | -7.7% | +5.0% | +1.6% | -7.1% | -7.1% | -3.4% | |
| – | +9.7% | +3.8% | +4.8% | +3.4% | -14.6% | +1.4% | +2.8% | +2.9% | -28.6% | -1.1% | -0.1% | |
| – | +0.0% | +0.4% | +0.0% | -0.5% | -0.9% | -0.6% | -3.0% | +0.2% | -0.4% | -0.5% | -0.9% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.